CASP3 and ovarian carcinoma: Interestingly, a study revealed that bexarotene treatment activated caspase-4 instead of caspase-3 and encouraged GSDME-dependent pyroptosis in ES2 cell line, indicating that bexarotene may be a novel agent for treating ovarian cancer [142].